Novel coronavirus disease (COVID-19) pandemic: A recent mini review
Author(s) -
Muhammad Fayyaz ur Rehman,
Chaudhary Fariha,
Aqsa Anwar,
Naveed Shahzad,
Munir Ahmad,
Salma Mukhtar,
Muhammad Farhan Ul Haque
Publication year - 2020
Publication title -
computational and structural biotechnology journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.908
H-Index - 45
ISSN - 2001-0370
DOI - 10.1016/j.csbj.2020.12.033
Subject(s) - coronavirus , virology , biology , pandemic , outbreak , orfs , pangolin , genome , untranslated region , genetics , rna , computational biology , covid-19 , gene , disease , open reading frame , medicine , infectious disease (medical specialty) , peptide sequence , paleontology , pathology
The COVID-19, caused by a novel coronavirus, was declared as a global pandemic by WHO more than five months ago, and we are still experiencing a state of global emergency. More than 74.30 million confirmed cases of the COVID-19 have been reported globally so far, with an average fatality rate of almost 3.0%. Seven different types of coronaviruses had been detected from humans; three of them have resulted in severe outbreaks, i.e., MERS-CoV, SARS-CoV, and SARS-CoV-2. Phylogenetic analysis of the genomes suggests that the possible occurrence of recombination between SARS-like-CoVs from pangolin and bat might have led to the origin of SARS-CoV-2 and the COVID-19 outbreak. Coronaviruses are positive-sense, single-stranded RNA viruses and harbour a genome (30 kb) consisting of two terminal untranslated regions and twelve putative functional open reading frames (ORFs), encoding for non-structural and structural proteins. There are sixteen putative non-structural proteins, including proteases, RNA-dependent RNA polymerase, helicase, other proteins involved in the transcription and replication of SARS-CoV-2, and four structural proteins, including spike protein (S), envelope (E), membrane (M), and nucleocapsid (N). SARS-CoV-2 infection, with a heavy viral load in the body, destroys the human lungs through cytokine storm, especially in elderly persons and people with immunosuppressed disorders. A number of drugs have been repurposed and employed, but still, no specific antiviral medicine has been approved by the FDA to treat this disease. This review provides a current status of the COVID-19, epidemiology, an overview of phylogeny, mode of action, diagnosis, and possible treatment methods and vaccines.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom